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Abstract
Tumor heterogeneity influences the clinical outcome of
patients with cancer, and the diagnostic method to measure the
tumor heterogeneity needs to be developed. We analyzed geno-
mic features on pairs of primary and multiple metastatic lymph
nodes from six patients with lung cancer using whole-exome
sequencing and RNA sequencing. Although somatic single-nucle-
otide variants were shared in primary lung cancer andmetastases,
tumor evolution predicted by the pattern of genomic alterations
wasmatched to anatomic location of the tumors. Four of six cases
exhibited a branched clonal evolution pattern. Lymphnodes with
acquired somatic variants demonstrated resistance to the cancer
treatment. In this study, we demonstrated that multiple biopsies
and sequencing strategies for different tumor regions are required
for a comprehensive understanding of the landscape of genetic
alteration and for guiding targeted therapy in advanced primary
lung cancer. Cancer Res; 76(22); 6568–76. 2016 AACR.
Introduction
Lung cancer is one of the most common malignancies in the
world, accounting for about 18% of all cancer-related deaths (1).
High lethality of advanced lung cancer may be closely involved
with its heterogeneous nature, presenting mostly in advanced
stages with a poor survival rate of less than 5% (2). Intratumoral
heterogeneity has been one of the major difficulties in treating
lung cancer successfully. Clonal diversity in lung cancer confers
the possibility of variable treatment responses in patients (3).
Comprehensive analysis on multiregional samples helps to
understand the tumor heterogeneity, but the multiregional sam-
ple acquisition in patients with refractory cancer is clinically
limited. Instead, we can utilize the multiple lymph node samples
harboring subpopulation of the primary tumor. Lung cancers
often spread first to lymph nodes near the tumor, known as hilar
or interlobar lymph nodes (N1), but they may also spread to
ipsilateral (N2) or contralateral (N3) mediastinal lymph nodes
(4). Lymph node metastasis in lung cancer is regarded as a strong
independent predictor of poor prognosis (4). Often primary
tumor location can determine whether lung cancer will spread
to the lymph nodes.
Understanding pathologic and molecular evolutionary pro-
cesses of lung cancer may provide greater insight toward devel-
opment of a suitable therapeutic guide (5). Although many
mutations detected in single biopsies of primary tumors are
common to several regions, other mutations are present only in
specific regions, suggesting clonal evolution. Thus, intratumor
heterogeneity (ITH) and intermetastatic heterogeneity are impor-
tant to consider for tumor biopsy strategies and treatment plans
(6). Recent works examining genomic tumor heterogeneity in
lung cancer havemainly focused onhow tumor heterogeneity and
tumor evolution are linked to the anticancer response due to
genomic alterations (7). However, the genomic heterogeneity
between primary tumor and lymph node metastases still remains
unclear.
In this study, we characterized genomic alterations and their
associations with treatment response by applying whole-exome
sequencing (WES) and RNA sequencing for multiple tumor
regions from 6 patients who were suspected to have primary lung
cancer withmultiple lymph nodemetastases or distantmetastasis
(Table 1). To evaluate the tumor heterogeneity of somatic altera-
tions, we classifiedmutations as trunkmutations presenting in all
tumor regions or non-trunk mutations (private and shared) in
specific region or subregions implying heterogeneous evolution.
Our study demonstrates subclonal diversity of multiregional
tumors and explores the connection between clonal patterns and
treatment response.
Materials and Methods
Patients and sample preparation
This study was approved by the Institutional Review Board
(IRB) of Samsung Medical Center (IRB approval no. SMC 2014-
03-140). Written informed consent was obtained from each
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patient. The study subjects were 6 Korean patients diagnosedwith
advanced lung cancer at Samsung Medical Center (Seoul, Korea).
The included cases met the following criteria: patients were
suspected to have primary lung cancer with multiple lymph node
metastases and no previous treatment. Each case includes a
primary tumor sample from bronchoscopic biopsy, hilar/inter-
lobar ormediastinal lymph node (N1, N2, andN3) samples from
endobronchial ultrasound guided-transbronchial needle aspira-
tion (EBUS-TBNA), normal bronchial mucosal tissue from bron-
choscopic biopsy, and peripheral blood (Supplementary Table
S3). Biopsy samples were snap frozen and stored in liquid
nitrogen until use. The study included 5 patients with non–small
cell lung cancer (NSCLC) and1patient with small-cell lung cancer
(SCLC; Table 1).Histology, clinical stage, and analyzed lesions are
summarized in Table 1.
Isolation of genomic DNA and RNA
Genomic DNA and RNA in tissues were purified using ALLPrep
DNA/RNA Mini Kit (Qiagen). Genomic DNA from peripheral
blood was extracted by QIAamp DNA Blood Mini Kit (Qiagen).
Genomic DNA concentration and purity were measured by a
Nanodrop 8000UV-Vis spectrometer (ThermoScientific Inc.) and
Qubit 2.0 Fluorometer (Life Technologies Inc.). To estimate DNA
degradation, DNA median size and DCt values were measured
with a 2200 TapeStation Instrument (Agilent Technologies) and
real-time PCR (Agilent Technologies), respectively. For RNA, the
concentration and purity was measured by Nanodrop and Bioa-
nalyzer (Agilent Technologies).
Whole-exome sequencing
GenomicDNA (1mg) fromeach samplewas sheared byCovaris
S220 (Covaris) and used for the construction of a library using
SureSelect XTHumanAll Exon v5 and a SureSelect XT Reagent Kit,
HSQ (Agilent Technologies) according to the manufacturer's
protocol. This kit is designed to enrich 335,756 exons of
21,058 genes, covering approximately 71 Mb of the human
genome. After enriched exome libraries were multiplexed, the
libraries were sequenced on a HiSeq 2500 sequencing platform
(Illumina). Briefly, a paired-end DNA sequencing library was
prepared through gDNA shearing, end-repair, A-tailing, paired-
end adaptor ligation, and amplification. After hybridization of the
library with bait sequences for 16 hours, the captured library was
purified and amplified with an index barcode tag, and library
quality and quantity were measured. Sequencing of the exome
library was carried out using the 100-bp paired-end mode of the
TruSeq Rapid PE Cluster kit and TruSeq Rapid SBS kit (Illumina).
Exome-seq data analysis
Sequencing reads were aligned to the UCSC hg19 reference
genome (downloaded from http://genome.ucsc.edu) using Bur-
rows-Wheeler Aligner (BWA; ref. 8), version 0.6.2 with default
settings. PCR duplications were marked by Picard-tools-1.8
(http://picard.sourceforge.net/), data cleanup was followed by
GATK and variants were identified with GATK-2.2.9 (https://
www.broadinstitute.org/gatk/; Supplementary Table S4). Then,
point mutations were identified by MuTect (https://github.com/
broadinstitute/mutect) and VarScan 2 (http://varscan.source-
forge.net) with paired samples. Perl script and ANNOVAR (9)
were used to annotate variants. Copy number variations were
identified by EXCAVATOR (10). The phylogenetic analysis was
performed on the basis of the binary sequence of somatic muta-
tion profiles. The phylogenetic tree was obtained by the Wagner
parsimony method.
RNA sequencing
Library construction for whole transcriptome sequencing was
performed using a TruSeq RNA Sample Preparation v2 Kit (Illu-
mina). Isolated total RNA was used in a reverse transcription
reaction with poly (dT) primers using SuperScriptTM II reverse
transcriptase (Invitrogen/Life Technologies) according to the
manufacturer's protocol. Briefly, an RNA sequencing library was
prepared through cDNA amplification, end-repair, 30end adeny-
lation, adapter ligation, and amplification. Quality and quantity
of the library were measured by Bioanalyzer and Qubit. Sequenc-
ing of the transcriptome library was carried out using the 100-bp
paired-end mode of the TruSeq Rapid PE Cluster kit and the
TruSeq Rapid SBS Kit (Illumina).
RNA sequencing data analysis
Reads from the FASTQ files were mapped against the hg19
human reference genome by using TopHat version 2.0.6 (http://
tophat.cbcb.umd.edu/; Supplementary Table S5). Raw read
counts mapped into genes were measured with the BAM format
file by HTSeq version 0.6.1 (11). Then, transcript abundance was
measured for 18,161 coding genes, and then scarcely expressed
genes were filtered out by the criteria ofmaximum read count >10
across all samples of each case. Read counts were normalized by
the TMM (trimmed mean of M-values) normalization method
(Supplementary Table S6). Thedifferentially expressed geneswere
identified using the DESeq R package (www-huber.embl.de/
users/anders/DESeq/). Fusion genes were detected by RNA-
sequencing and Cancer Panel sequencing and they were visual-
ized in genome regions using the IGV (Integrative Genome
Viewer) tool (http://www.broadinstitute.org/igv/). The gene-set
variance analysis (12) was performed with REACTOME gene sets
to identify enriched pathways in each sample. Then, differential
gene sets between sample groups were identified using limma R
package.
Clonality analysis
Subclones were obtained by clustering cancer cell fractions by
PyClone, which can deconvolute the tumor into subclones using
a hierarchical Bayesian clustering model (13). The input data
were generated with somatic single-nucleotide variations (SNV)
Table 1. Summary of clinical features of six patients with lung cancer patients
Case # Sex/age Smoking Histology Analyzed lesions Clinical stage
TH1 M/74 50 PY SCLC RML, 4R (N2), 7 (N2), 4L (N3) T2bN3M0
TH2 M/80 6 PY NSCLC, ADC LLL, 4L (N2), liver (M1b) T1bN3M1b
TH3 M/62 90 PY NSCLC, SCC RUL, 11Rs (N1), 4R (N2) T2aN3M0
TH4 M/48 30 PY NSCLC, SCC RBI, 11Rs (N1), 7 (N2), 4L (N3) T2aN3M0
TH5 F/66 Never NSCLC, ADC LUL, 11L (N1), 7 (N2), 4R (N3) T1bN3M1b
TH6 M/64 30 PY NSCLC, SCC LUL, 4L (N2), 7 (N2), 2R (N3) T4N3M1b
Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; RUL, right upper lobe; LLL, left lower lobe; LUL, left upper lobe; M, male; F, female;
PY, pack-year.
Genetic Evolution in Metastatic Lymph Nodes of Lung Cancer
www.aacrjournals.org Cancer Res; 76(22) November 15, 2016 6569
on August 13, 2019. © 2016 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst September 13, 2016; DOI: 10.1158/0008-5472.CAN-16-0873 
detected byMuTect and copy number variations corresponding to
SNVs. Step filtering the SNVs with large credible intervals in the
previous stage was applied to remove those with noninformative
posterior distributions. The subclones between primary tumors
and each lymph node were compared using the density plot of
cancer cell fractions.
Results
Genomic alterations ofmetastatic lymph nodes correlated with
anatomic region
Somatic SNVs including missense, nonsense, and splicing
were identified by WES on samples from 6 patients with lung
cancer (TH1–TH6; Fig. 1 and Supplementary Fig. S1). Patients
were presented sorted by the rate of concordance in somatic
mutations between tumors of each case. While the number of
somatic SNVs in each patient varied from 65 to 493 (Supple-
mentary Table S1), the rate of concordance in somatic muta-
tions between distinct lymph nodes and primary lung cancer
was 71.6%  19.1% for the six cases. Comparing concordance
rate between the primary tumor and each node, patient TH10s
SCLC was the most homogeneous while patient TH6's squa-
mous cell carcinoma (SCC) was the most heterogeneous
(Fig. 1C). Patient TH3 with new distant metastasis to kidney
during the follow-up had twice as many mutations (> 400) as
the other cases. The large number of mutations may be asso-
ciated with quite tobacco smoking of this patient [90 pack-years
(PY); ref. 14]. The trees of dynamic tumor evolution show
patterns of intermetastatic genetic heterogeneity in metastatic
lymph nodes (Fig. 1B).
Anatomic location of the primary tumor could provide clues to
advanced lung cancer tumor evolution. Three lymph nodemetas-
tases in patient TH1 shared most mutations with the primary
tumor in the right middle lobe (Fig. 1B). This suggests that
multiple lymph node metastases might have occurred at the
Figure 1.
The trees of dynamic tumor evolution representing patterns of intermetastatic mutational heterogeneity in lymph node metastases of advanced lung cancers. A,
analyzed lesions for each case are displayed. The black and orange circles are primary lesions and metastasis sites, respectively. LUL, left upper lobe; RUL,
right upper lobe; RML, right middle lobe; LLL, left lower lobe; RBI: right bronchus intermedius; 11L N1, left interlobar lymph node; 7 N2, subcarinal lymph node; 4L N2,
left lower paratracheal lymph node; 4R N2, right lower paratracheal lymph node; 2R N3, right upper paratracheal lymph node; 4L N3, left lower paratracheal
lymph node; 4R N3, right lower paratracheal lymph node; 11Rs N1, right superior interlobar lymph node; M1b, distant metastasis. B, branches in divergence trees
include trunk mutations shared in all the tumors (thick blue line), mutations shared with primary site (thin blue line), shared mutations between lymph nodes
(green line), and private mutations (red line). The number of somatic mutations (muts) in each branch is shown. C, tumor cases are listed according to the
average concordance rate ofmutations between primary site and lymph nodes.D,dendrogram representing the relative similarity between gene expression profiles.
Cancer census genes (572) were used.
Um et al.
Cancer Res; 76(22) November 15, 2016 Cancer Research6570
on August 13, 2019. © 2016 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Published OnlineFirst September 13, 2016; DOI: 10.1158/0008-5472.CAN-16-0873 
similar time points. The primary tumor site of patient TH4 was
located in the right bronchus intermedius (RBI). Over half of the
mutations in the primary tumor were shared with each lymph
node. Among three lymph nodes, N1 shared the most mutations
with the primary tumor and it is closely located near the primary
site. Many mutations between N2 and N3 were concordant and
N2 is closer to the primary tumor than N3. It is likely that
metastasis of the N2 tumor occurred earlier than the N3 tumor.
The dendrogram representing the relative similarity between gene
expression profiles of cancer-related genes, generated by hierar-
chical clustering, show a pattern consistent with the branching
pattern of mutations (Fig. 1D).
From the branching pattern of mutations, we analyzed muta-
tion spectra analyzed for trunk and non-trunk mutations
(Fig. 2A). A previous study reported that the proportion of C>A
transversion was significantly decreased in late-occurring muta-
tions from The Cancer Genome Atlas (TCGA) lung adenocarci-
noma and lung squamous cell carcinoma smokers and former
smokers (5). TH1 and TH3 patients showed typical mutation
profile for heavy smokers, but their profiles are significantly
decreased in non-trunk mutations (P ¼ 4. 7  105 and 5.1 
103, binomial test). The decreased proportion of C>A transver-
sion is accompanied by an increased pattern of C>T and C>G
mutations at TpCpW sites, which was reported to be induced by
APOBEC cytidine deaminase (15).
Major mutations frequently observed in lung cancers were
identified in six cases (Fig. 2B). TP53, ROS1, TSC2, SMARCA4,
and ATMmissense mutations, ARID1A nonsense mutations, and
RB1 splicing mutations were commonly found in multiple
regions of each case.However,manymutations including PIK3CA
(H1047R) andHRAS (Q61R) were found in only specific regions.
Both mutations were consistently found in the same samples in
RNA sequencing (RNA-seq) data. Clinical sequencing on single
biopsy of primary tumor might miss driver mutations present in
low fractions of primary tumor. EML4-ALK fusiononcogeneswere
detected in TH2 (6 PY) and TH5 (never-smoking patient; Sup-
plementary Fig. S2). This result supports previous studies on lung
adenocarcinomas showing that EML4-ALK fusion was correlated
with non- or light smoking (<10 PY; refs. 16, 17). Furthermore,
EML4-ALK fusion is mutually exclusive for EGFR and KRAS
mutations in patients with NSCLC (18–20) and this was also
true for the patients in our study.
Figure 2.
The SNV spectrum and mutation profile. A, the spectrum of substitutions in trunk and non-trunk mutations. Each bar represents the proportion of each
type of substitution. PY, pack-year. B, the heatmap of somatic mutations (including missense, nonsense, and splicing) detected in in lung cancer–associated genes.
The listed genes were sorted by the mutation frequency observed in lung cancer cohorts of TCGA ADC and SCC.
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Clonal evolution analysis from transcriptome profile of
metastatic lymph nodes
Because lymph nodes obviously contain infiltrated nontumor
cells, we need to select cancer-associated gene sets excluding genes
related to stroma and lymphocytes for the correlation analysis.
The primary tumor and three lymph nodes of patient TH1 had
highly similar somatic SNV profiles (Fig. 1) and copy number
alteration patterns (Fig. 4). However, minor differences were
detected in clonality comparison (Fig. 3A). Unlike lymph node
7, 4L and 4R each have additional clones thatmight appear in late
stage in tumorigenesis. Those clones contained common mis-
sense mutations of FAXDC2, HLCS, ADAM2, and ZNF585A in
both nodes. While station 7 lymph node of patient TH1 did not
exhibit the differential expression profile, gene expression in
lymph nodes 4L and 4R was rather distinct to the primary tumor
(Fig. 3B). ALK was highly expressed in 4L and 4R (>100-fold)
compared with matched normal tissue, but not in lymph node 7.
ALK was also highly expressed in 4L and 4R (>3-fold) and 7 (1.5-
fold) comparing with primary cancer. Patient TH1 had RB1
(c.862-1G>T), TP53 (H47L), and AKT3 (E17K) mutations (Fig.
Figure 3.
The genomic and transcriptomic differences between multiple lymph nodes of patients TH1 (A–D) and TH5 (E–G). A and E, the density plots of cancer cell fraction
(CCF) between the primary site and lymph node metastases. B and F, the scatter plots for similarity of gene expression profiles between the primary site
and lymph node metastases. Differentially expressed cancer-related genes (>2-fold change) are highlighted in red and green. C and G, the phylogenetic trees were
obtained on the basis of the binary sequence of somatic mutation profiles by theWagner parsimonymethod.D, left, the volcano plots of gene-set variance analysis
(GSVA) score difference. Significantly enriched gene sets are highlighted in red (Padj < 0.05 and log ratio > 0.5). Right, the heatmaps of gene expression. They
include genes involved in "Signaling by NOTCH2/3" set for patient TH1.
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3C). It has been reported that RB1 is commonly mutated in SCLC
(21). In addition, a silent EGFRmutation (Q787) was detected in
4L and 4R. On the basis of profile similarity, pathways showing
differential expressionpatterns between groupof 4L and4Rversus
7 were identified (Fig. 3D; Supplementary Table S2). Among
them, genes belonging to "signaling by NOTCH2/3" pathway
(Padj¼ 0.034) showed lower levels of expression in nodes 4L and
4R than in 7. A previous study reported that activation of Notch
signaling is associated with suppression of growth and arrest of
the SCLC cells (22). Furthermore, Notchmay be a keymediator of
resistance to chemotherapy as well as radiotherapy (23).
TH5 had highly heterogeneous mutation profiles with addi-
tional subclones in three lymph nodes (Fig. 3E), and the gene
expression profile of the primary tumor was different from each
lymphnode (Fig. 3F).Many cancer-related genes that exhibit high
or low expression (> 2 fold change) were those expressed in
human lymphocytes including Fc gamma receptor II-b
(FcgRIIB/CD32B), IL21R, IL7R, and PTPRC. EML4-ALK fusion
oncogenes were commonly detected in all tumors in TH5 patient
and a novel ARID1BQ421Emissensemutationwas found in only
lymph node 7 (Fig. 3G).
TH2 and TH3 had commonly additional subclones in meta-
static tumors (Supplementary Fig. S3A and S3B). The p.L127V
mutation in CUL3 known as a tumor suppressor in lung cancer
(24) was detected in additional subclone of TH3 4R. Meanwhile
TH4 and TH6 had additional subclones in specific metastatic
tumors (Supplementary Fig. S3C and S3D). The expression pat-
terns of lymph nodes were highly similar to corresponding clonal
patterns. AKT2was highly expressed in 4L of TH6 (>5.4-fold), but
not in lymph node 7 and 2R (<1.0-fold). This gene plays an
important role in lung cancer cell proliferation and colony growth
(25). Significantly different activation status of pathways between
lymph nodes and primary tumor was found (Supplementary
Table S2).
Correlation of treatment responses with clonal evolution
pattern of metastatic lymph nodes
Five of 6 patients in this study received treatment, and one
patient, TH6, declined treatment. Clinical responses of 5 patients
were quite personal to each treatment modality (Table 2). Patient
TH1 was treated with etoposide/carboplatin #3 and radiation.
Although mutation profiles of this patient were highly homoge-
neous for primary and multiple nodes, treatment responses
showed a heterogeneous pattern. The primary tumor and lymph
node 7 metastasis decreased in size while 4R and 4L lymph node
metastases were not significantly responsive to treatment. It is
worth noting that this result is consistent with the clonality
pattern, as additional clones with ALK overexpression were pres-
ent in 4R and 4L (Fig. 3E).
Patient TH2 had minor alterations in metastatic lymph nodes
with trunk mutation like EML4-ALK fusion (Supplementary Fig.
S2), which was target for crizotinib. Relatively homogeneous
genomic alterations might explain the better response to the
target therapy.
Patient TH3 was treated with concurrent chemoradiation ther-
apy including weekly taxol/cisplatin. The patient did not respond
to the treatment and had rapidly progressing systemic metastasis
during follow-up. The patient's poor response to the treatment
could be partly explained by higher load of mutation than other
cases (Supplementary Fig. S1).
Patient TH4 was treated with concurrent chemoradiation ther-
apy including weekly taxol/cisplatin. Complete resolution was
seen at lymph node 4L and a decrease in primary tumor size was
noticed. However, lymph node metastases 11Rs and 7 showed
progression after an initial response. These heterogeneous pro-
gressions after treatment may be related to the heterogeneity of
each lesion. Mutations in LPP and ABCB1 were found in addi-
tional subclones of nodes 11Rs and 7, respectively (Supplemen-
tary Table S1). Notably, P-glycoprotein ABCB1 is a known mul-
tidrug transporter and has been associated with drug resistance in
human tumors (26). Thismay explainwhy lymphnode 7 shows a
unique treatment response, although its overall genomic and
transcriptomic profiles are highly similar to those of lymph node
4L in this patient.
Patient TH5 was treated with gemcitabine/carboplatin #4, and
the primary lesion responded to treatment while the three met-
astatic lymph nodes showed continuous tumor progression.
Limited response of patient TH5 was associated with the high
degree of tumor heterogeneity in metastatic lymph nodes, exhi-
biting additionally produced subclones (Fig. 1B).
Figure 4.
The copy number alterations of primary
and lymph nodes. Segmentation
values (log2 ratios) are plotted. The
amplification and deletion are
presented by red and blue.
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Evolution of distinct subclones in early metastasis to a distinct
lymph node
The primary tumor of patient TH6 spread to lymphnodes 7, 4L,
and 2R (Supplementary Fig. S4A). Two of these nodes (station 7
and 2R) have highly similar somatic mutation profiles, copy
number alteration amplifications, and deletions, while 4L
showed a distinctive alteration pattern (Fig. 4). Overall gene
expression pattern of 4L is consistently different from those of
other two nodes as measured by mutations, copy number vari-
ation (CNV), and clonality (Supplementary Fig. S4B and S4C). 4L
is located relatively near the primary site (left upper lobe), yet the
concordance of mutations with the primary tumor is very low
(15.3% of primary mutations). Furthermore, this metastasis also
showed low concordance rate with other lymph nodemetastases.
This suggests that metastasis to 4L occurred in this patient at a
relatively early stage of tumor progression compared with the
other two metastases. The percentage of trunk mutations is only
8.2% of the total distinct mutations (Supplementary Fig. S5A).
Among thosemutations, a keymutationwithin a potential driver,
ATM, was found. ATM plays a role as a regulator of the p53
signaling pathway, and it has been reported as a tumor suppressor
gene in lung adenocarcinoma (27). ATMmutationmay accelerate
lung cancer formation by acting upstream of p53. Interestingly,
only 4L lymph node has a PIK3CA driver mutation in this patient.
PIK3CA H1047R mutation has been known to be one of most
frequently observed PI3-kinase mutations in human cancers.
Mutant PIK3CA proteins are known to activate the downstream
signaling cascade and induce oncogenic transformation in vitro
(28). NSCLCs harboring PIK3CA-activating mutations have
shown sensitivity to the dual PIK3CA/mTOR inhibitor PI-103
(29). CNV pattern showed that 4L lymph node station had 10p15
and 19q13 chromosomal amplifications that appeared promi-
nently, compared with other two lymph nodes. Amplification of
Akt in human malignancies has been known to lead to hyper-
activation of downstream signaling. 19q13 chromosomal ampli-
fications, including AKT2, are associated with tumor aggres-
siveness (30). 12p13.33 amplification appeared in all the lymph
nodes and in the primary tumor of this patient. A recent study
reported that the recombination repair gene RAD52, within the
12p13.33 region, is associated with the risk of lung squamous cell
carcinoma development (31). The expression level of genes
belonging to the targetable PI3K/RTK/RAS oncogenic pathway
were observed to be above background expression levels of the
TCGA squamous cell carcinoma cohort (n¼ 495; Supplementary
Fig. S4C). Most of these genes were highly expressed in the 4L
lymph node. Among them, higher expression of AKT2 (Supple-
mentary Fig. S5B) and RASA1 genes in 4L was significantly
correlated with poor clinical outcome by predicting risk from the
TCGA SCC cohort (P ¼ 0.012 and P ¼ 0.015, respectively). The
previous study suggested that AKT activation may occur early in
tumor progression of lung cancer (32). It is likely that PIK3CA
mutation and ATK2 amplification evoke abnormal expression of
downstream genes involved in oncogenic pathways.
Discussion
In this study, we characterized genomic alterations and their
associations with treatment response by performing WES and
RNA-seq on multiple biopsy specimens from different anatomic
regions in advanced stage lung cancers. The patients with advanced
stage lung cancerusually donotundergo surgery to receive a biopsy
for the most representative lesion. Histologic diagnosis, genotyp-
ing, and treatment decision are usually based on a single biopsy
specimen. However, tumor heterogeneity can be an important
obstacle to successful targeted therapy in these patients as the
current strategy of biopsy for themost representative lesion cannot
reflect the whole landscape of tumor heterogeneity. Although
previous studies have addressed the issue of tumor heterogeneity
in patients with early-stage lung cancers (5, 6), they are not usually
considered the candidate for the targeted therapy.
In this study, tumor heterogeneity and clonal diversity were
associated with the heterogeneous treatment response in patients
with primary lung cancer. The tumor heterogeneity could influ-
ence the clinical outcomes of patients with cancer, thus under-
standing the correlation between tumor heterogeneity and genetic
alternations will lead to the establishment of a new strategy for
targeted therapy in primary lung cancer. Targeted therapy showed
an initial treatment response but disease progression during the
treatment in patients with primary lung cancer (33, 34). This
phenomenonmay be attributable to the acquired resistance to the
targeted therapy or clonal diversity with multiple therapeutic
targets (35, 36). If we perceive multiple driver mutations in the
tumor or metastatic lymph node, we may need to combine
targeted therapies for the multiple therapeutic targets.
Mutation profiles obtained from WES or high-depth targeted
panel sequencing will provide information for making treatment
decisions for advanced lung cancers with metastasis. However,
mutation profile alone is not sufficient for full understanding of





TH1 Etoposide/carboplatin #3 & radiotherapy Heterogeneous response (primary tumor /7 lymph nodes: decrease in size but
4R /4L lymph nodes: no change in size) [overexpression of ALK in 4R and 4L]
TH2 Crizotinib for 9 months Primary tumor, 4L lymph node, liver: decrease in size [homogeneous genomic
alteration]
TH3 Concurrent chemoradiation therapy
(weekly taxol/cisplatin #7)
Stable disease in primary tumor/lymph nodes but new metastasis in kidney
[higher load of mutation]
TH4 Concurrent chemoradiation therapy
(weekly taxol/cisplatin #7)
Heterogeneous progression (complete resolution of 4L lymph node and decrease
in primary tumor but progression after initial response in 11Rs/7 lymph nodes)
[additional subclones of 11Rs and 7 lymph node]
TH5 Gemcitabine/carboplatin #4 Heterogeneous progression (no progression in primary tumor but progression in
11L, 7, and 4R lymph nodes) [heterogeneous genomic alteration between
multiple nodes]
TH6 The patient rejected any treatment N.A.
Abbreviation: N.A., not applicable.
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the treatment response and clinical phenotype. Additional infor-
mation such as RNA expression and epigenetic features may be
needed. TH1 has ALK expression as well as exon 20 mutations of
EGFR in only 4R and 4L. Exon 20 mutations are associated with
resistance to anti-EGFR therapies (37). In TH4, private mutation
in ABCB1 known as a known multidrug transporter may explain
partially why lymph node 7 shows poor treatment response.
However, there may be yet unknown factors causing resistance
to treatment in transcription level. Poor treatment response of
three lymph nodes in TH5 may be due to the private mutation as
well as high expression of the resistance gene. Lymph node 7 has
ARID1B mutation that may be associated with treatment failure
like in neuroblastoma (38). 11L and4R showedhigher expression
level (> 14 fold change) of ABCC3 gene than primary (< 8-fold).
ABCC3 has been known to be amarker formultidrug resistance in
NSCLC (39). Furthermore, pathway alterations according to
aberrant gene expression could confer drug resistance. Patient
TH6 has a PIK3CA H1047R mutation in only one region, as seen
in another heterogeneity study (5). In this patient, an inhibitor
targeting the PI3K/mTOR signaling axis as part of a combination
therapy may be suggested. In patients TH1, TH4, and TH5,
heterogeneous response or progression were associated with
tumor heterogeneity in each lesion after cytotoxic chemotherapy
or concurrent chemoradiation therapy. Thus, an integrative
understanding of genomic and transcriptomic alterations from
biopsies of multiple regions is critical for therapeutic decision
making in advanced lung cancers with metastasis.
Interestingly, tumor heterogeneity of metastatic lymph nodes
was associated with the proximity from the primary tumor and
lymphatic drainage system. In patient TH4, the primary tumor
(RBI)was in close proximity to 11Rs (N1; Fig. 1A).N1 sharedmore
mutationswith the primary tumor thanN2 (station 7) orN3 (4L).
ManymutationsbetweenN2andN3were concordant, butN2was
closer to the primary tumor than N3. Station 7 (subcarinal lymph
node) is a midline lymph node considered as a crossroad where
lymphatic vessels from all lobes of the lungs meet, and metastasis
to the contralateral lymphnodes occur via station 7 (40). Likewise,
inpatientTH6, theprimary tumor (left upper lobe) is likely tohave
metastasized first to 4L and then to the contralateral 2R via station
7 based on tumor heterogeneity and evolution pattern (Fig. 1A).
The determinants of stemness are able to be the contributors
that affect therapy failure (41). The genetic and nongenetic
mechanism as well as cancer stem cells (CSC) can be sources of
tumor heterogeneity. The observation of transcriptional signa-
tures associated with CSC from multiple tumors could be highly
predictive in clinical outcome as well as therapeutic resistance in
patients with advanced lung cancer. Analysis of branched clonal
evolution pattern will lead us to understand mechanisms of
tumor heterogeneity, the link with therapy resistance, and CSC
biologies. Finally, our data can serve as new evidence for the old
concept of the mediastinal drainage system based on intermeta-
static tumor heterogeneity and clonal evolution.
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